An ongoing phase 3 trial, TeliMET NSCLC-01 (NCT04928846), is comparing Teliso-V monotherapy versus docetaxel in c-MET-overexpressing EGFR-WT NSQ NSCLC that had previously progressed on therapy [44]. Here, MET is linked to non-small cell lung carcinoma.